Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen Lifotronic Technology Co., Ltd. (688389.SS)
Shenzhen, CN
Established in 2008 and headquartered in Shenzhen, China, Shenzhen Lifotronic Technology Co., Ltd. specializes in the design, production, and distribution of a wide range of medical devices throughout China, addressing both diagnostic and therapeutic requirements. Its extensive portfolio includes In Vitro Diagnostic (IVD) products, featuring sophisticated analytical instruments such as HPLC systems for hemoglobin and HbA1c measurements, automated ECL immunoassay analyzers, and hematology analyzers. The company also provides Point-of-Care Testing (POCT) solutions, including immunofluorescence analyzers, alongside molecular diagnostics equipment like automated nucleic acid purification systems and real-time PCR platforms. Additionally, Lifotronic offers rapid test kits for key infectious diseases such as COVID-19, malaria, dengue, and influenza A and B. In the therapeutic sector, the company delivers a diverse array of solutions. Respiratory and ICU products encompass video laryngoscopes, warmer units with disposable blankets, high-flow humidification systems, high-frequency chest wall oscillation devices, and intermittent pneumatic compression pumps. For wound care, offerings include negative pressure wound therapy, ultrasound-assisted wound debridement, and wound healing light therapy. Pain management is addressed through ESWT (Extracorporeal Shockwave Therapy) devices, specifically electromagnetic and extracorporeal shockwave systems. Furthermore, Lifotronic is active in medical and aesthetic laser technologies, providing intensive pulsed light systems, fractional CO2 laser systems, Q-switched Nd:YAG laser systems, and fiber laser hair removal systems.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -3.84% | -9.89% | -16.48% | -15.09% | -9.40% | -9.26% | -55.74% | -58.56% | -40.09% | -40.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-9.6% Q1'26: +20.9% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-46.9% Q1'26: -38.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+20.3% Q1'26: -1.7% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+17.7% ★ Q1'26: +15.1% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+19.5% ★ Q1'26: +12.8% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+1.5% Q1'26: -1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×1.83× ★ Q1'26: 0.96× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
553.82M
est: 554.00M (0.0%)
|
778.11M
est: 770.00M (+1.1%)
|
983.04M
est: 1.04B (-5.6%)
|
1.15B
est: 1.18B (-2.7%)
|
1.15B
est: 1.26B (-8.5%)
|
1.04B
est: 1.03B (+1.3%)
|
1.22B
1.18B – 1.25B
+18.6% YoY
|
1.41B
1.35B – 1.48B
+16.3% YoY
|
1.64B
1.62B – 1.65B
+15.8% YoY
|
| EBITDA |
168.39M
est: 174.98M (-3.8%)
|
220.86M
est: 243.20M (-9.2%)
|
282.89M
est: 328.80M (-14.0%)
|
376.89M
est: 347.90M (+8.3%)
|
421.48M
est: 370.89M (+13.6%)
|
217.91M
est: 302.92M (-28.1%)
|
359.37M
349.41M – 369.33M
+18.6% YoY
|
417.88M
397.83M – 437.94M
+16.3% YoY
|
483.89M
479.99M – 487.78M
+15.8% YoY
|
| EBIT |
156.24M
est: 160.00M (-2.3%)
|
203.11M
est: 222.39M (-8.7%)
|
259.76M
est: 300.66M (-13.6%)
|
348.65M
est: 316.27M (+10.2%)
|
386.93M
est: 337.16M (+14.8%)
|
183.36M
est: 275.37M (-33.4%)
|
326.69M
317.63M – 335.74M
+18.6% YoY
|
379.88M
361.65M – 398.11M
+16.3% YoY
|
439.88M
436.34M – 443.42M
+15.8% YoY
|
| Net Income |
143.95M
est: 145.80M (-1.3%)
|
190.35M
est: 192.96M (-1.4%)
|
251.48M
est: 257.29M (-2.3%)
|
328.58M
est: 365.94M (-10.2%)
|
345.39M
est: 411.14M (-16.0%)
|
186.09M
est: 246.68M (-24.6%)
|
238.40M
228.00M – 268.24M
-3.4% YoY
|
282.49M
280.52M – 316.72M
+18.5% YoY
|
356.32M
335.63M – 377.01M
+26.1% YoY
|
| SGA |
115.47M
est: 86.10M (+34.1%)
|
155.21M
est: 119.67M (+29.7%)
|
193.63M
est: 161.79M (+19.7%)
|
220.54M
est: 203.77M (+8.2%)
|
221.81M
est: 217.23M (+2.1%)
|
86.47M
est: 177.42M (-51.3%)
|
210.48M
204.65M – 216.31M
+18.6% YoY
|
244.75M
233.01M – 256.50M
+16.3% YoY
|
283.41M
281.13M – 285.69M
+15.8% YoY
|
| EPS |
0.34
est: 0.34 (+0.0%)
|
0.45
est: 0.45 (+0.0%)
|
0.60
est: 0.60 (+0.0%)
|
0.77
est: 0.85 (-9.2%)
|
0.81
est: 0.95 (-14.7%)
|
0.43
est: 0.57 (-24.6%)
|
0.57
0.53 – 0.62
+0.6% YoY
|
0.69
0.65 – 0.73
+20.3% YoY
|
0.82
0.78 – 0.87
+19.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 81.4K | 0.39% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 47.1K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 36.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hong Wang | Accounting Supervisor, Chief Financial Officer, Director | — | female |
| Liang Qiu | Deputy General Manager | — | male |
| Man Lu | Board Secretary | — | female |
| Ming Long Hu | Director & GM | — | male |
| Ying Zeng | Director & Deputy GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688389.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
